A vaccine that targets qualities of the virus responsible
for replicative capacity could have an important impact on disease progression and secondary transmission.»
Not exact matches
«This suggests lowering viral
replicative capacity and the resulting immune activation might have benefits, in terms of morbidity and mortality,
for individuals whether they remain treatment naïve or go on antiretroviral therapy.
«These results reinforce our previous findings suggesting that interventions that affect
replicative capacity can not only impact disease progression, but also the efficiency of transmission to other people,» says senior author Eric Hunter, co-director of the Emory Center
for AIDS Research, Georgia Research Alliance Eminent Scholar and a professor of pathology and laboratory medicine at Emory University School of Medicine.
This may have important implications
for cure strategies aimed at eliminating the viral reservoir, as individuals infected with low
replicative capacity viruses may have smaller latent viral pools that may be easier to eradicate.
This suggests that both ccr5 and cxcr4 can be genetically targeted simultaneously
for the treatment of HIV infection, while preserving the
replicative capacity of the CD4 + T cells.